AFP and metabolic dysfunction-associated steatohepatitis: A second post-hoc analysis was conducted by random sampling of 20 patients’ data from the CELESTIAL study so that the population had the same distribution as the prior sorafenib cohort of this study of the following four baseline factors: extrahepatic spread and/or macrovascular invasion (Y/N), ECOG performance status (0/ > 0), AFP level (< 400/ ≥ 400 ng/mL) and HCC etiology of nonalcoholic steatohepatitis (Y/N).